NAFDAC Places Mofus Nigeria Products on Watchlist Amid Ongoing Regulatory Investigation

The National Agency for Food and Drug Administration and Control (NAFDAC) has placed products marketed by Mofus Nigeria Ltd on its watchlist while it investigates significant regulatory non-compliance and potential misrepresentation linked to the products. The investigation involves Ayrtons Saunders Ltd, UK, and Pharmaserve (North West) Ltd, and is being conducted under case reference NAFDAC/PMS/2026/0029. NAFDAC has advised healthcare professionals, medicine suppliers, and the public to exercise caution and report any suspected quality or regulatory concerns.

Me & You Pharma Takeaways

• NAFDAC has placed products marketed by Mofus Nigeria Ltd on its watchlist pending an ongoing investigation.
• The investigation involves Ayrtons Saunders Ltd, UK, and Pharmaserve (North West) Ltd.
• NAFDAC identified significant regulatory non-compliance and potential misrepresentation requiring further investigation.
• The case is classified as high risk and remains under active investigation.
• NAFDAC has advised stakeholders to exercise caution when procuring, distributing, dispensing, or using the affected products.
• The agency has not stated in this alert that all products marketed by Mofus Nigeria Ltd are confirmed counterfeit or unsafe; the investigation is still ongoing.

What Happened?

NAFDAC has announced that products marketed by Mofus Nigeria Ltd have been placed on its watchlist while the agency conducts a regulatory investigation.

The investigation follows findings of significant regulatory non-compliance and potential misrepresentation involving products associated with Mofus Nigeria Ltd, Ayrtons Saunders Ltd in the United Kingdom, and Pharmaserve (North West) Ltd.

The matter is being investigated under reference number NAFDAC/PMS/2026/0029. NAFDAC has classified the risk level as high and has commenced surveillance and stakeholder notification activities.

The agency has also encouraged healthcare professionals, distributors, medicine vendors, and consumers to report suspected product defects, adverse events, authentication concerns, or other regulatory irregularities.

Why It Matters To Your Health

When a medicine or healthcare product is placed on a regulatory watchlist, it means the relevant authority has identified concerns that require further assessment. This is important because medicines must meet established standards for quality, safety, authenticity, and regulatory compliance before and during their circulation.

In this case, NAFDAC identified significant regulatory non-compliance and potential misrepresentation and has therefore initiated a formal investigation. However, the investigation is still ongoing, meaning the available information does not establish that every product associated with Mofus Nigeria Ltd is unsafe or falsified.

The watchlist status is therefore a reason for caution and increased regulatory scrutiny, rather than confirmation of a final finding.

For healthcare professionals, pharmacies, distributors, and medicine vendors, maintaining accurate purchasing and distribution records is particularly important. Traceability can help regulators identify where affected products have been distributed if further action becomes necessary.

For patients, the alert reinforces the importance of obtaining medicines from licensed pharmacies and authorized suppliers. Patients should also avoid purchasing medicines from unknown or unverified sources, particularly when there are concerns about product authenticity.

What You Can Do

If you are a patient, pharmacist, healthcare facility, distributor, or medicine vendor:

• Exercise caution when purchasing or handling products marketed by Mofus Nigeria Ltd.
• Obtain medicines from licensed pharmacies and authorized suppliers.
• Keep receipts, invoices, and other purchasing or distribution records where possible.
• Do not use a product if its packaging, labeling, appearance, or authenticity raises concerns.
• Speak with a pharmacist if you are uncertain about the authenticity or appropriate use of a medicine.
• Report suspected product defects, adverse reactions, falsification, or other regulatory concerns to NAFDAC.

Healthcare facilities and distributors should cooperate with NAFDAC if approached as part of the ongoing investigation.

Understanding The Issue

NAFDAC’s decision to place the products on its watchlist follows findings that the agency considers significant enough to warrant further regulatory investigation. The concerns include regulatory non-compliance and potential misrepresentation involving the products and entities identified in the alert.

The case involves Mofus Nigeria Ltd as the Marketing Authorisation Holder, Ayrtons Saunders Ltd as the identified product/entity name, and Pharmaserve (North West) Ltd as the manufacturer. The country of origin listed in the alert is the United Kingdom, while the registration status is stated as registered.

The case has been assigned reference number NAFDAC/PMS/2026/0029 and is currently classified as an ongoing investigation. NAFDAC has also identified the risk level as high.

Being placed on a watchlist should not automatically be interpreted as proof that a product is counterfeit or harmful. In this case, NAFDAC has stated that the investigation is ongoing. The purpose of the regulatory process is to establish the facts and determine what further action, if any, is required.

NAFDAC has responded by initiating formal investigation procedures, increasing surveillance, notifying relevant stakeholders, and encouraging reports concerning potential quality problems or irregularities. These measures allow the agency to gather additional information while assessing the products and entities involved.

For consumers, one of the most important safeguards is purchasing medicines through legitimate channels. Licensed pharmacies and authorized suppliers provide greater accountability and traceability than informal or unverified sources. Patients should also be cautious about medicines with unusual packaging, unclear labeling, unexplained changes in appearance, or other signs that raise questions about authenticity.

Healthcare professionals and medicine suppliers also have an important role in maintaining the integrity of the medicine supply chain. Keeping appropriate procurement and distribution records allows products to be traced more efficiently if a regulatory concern is identified.

At this stage, the investigation remains ongoing. Patients should therefore avoid spreading unverified claims about the companies or products involved and instead rely on official regulatory updates as NAFDAC’s investigation progresses.

When To Speak With A Healthcare Professional

Speak with a pharmacist or doctor if:

• You are currently using a product marketed by Mofus Nigeria Ltd and have concerns about its authenticity or quality.
• You notice unusual changes in a medicine’s packaging, labeling, appearance, smell, or physical condition.
• You experience an unexpected reaction after taking a medicine.
• You are unsure whether a medicine was obtained from a legitimate source.
• You have questions about whether you should continue using a particular product.

Seek urgent medical attention if you experience severe or rapidly developing symptoms after taking any medicine.

Healthcare professionals, distributors, and consumers should report suspected quality defects, adverse events, or product authentication concerns to NAFDAC.

Join The Me & You Pharma Community

Stay informed about NAFDAC alerts, medicine recalls, counterfeit drug warnings, pharmacist-led medication advice, and important health news. Join the Me & You Pharma community to receive reliable updates and practical information that can help you make safer decisions about medicines for yourself and your family.

Medical Disclaimer

This article is provided for general educational and informational purposes only and is based on information released by the National Agency for Food and Drug Administration and Control (NAFDAC).